A selective antagonist of mineralocorticoid receptor eplerenone in cardiology practice

被引：0
|
作者：
Gegenava, B. B. [1 ]
Drapkina, O. M. [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow 119991, Russia
来源：
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | 2015年 / 11卷 / 02期
关键词：
aldosterone; heart failure; atrial fibrillation; chronic renal failure; albuminuria; eplerenone; spironolactone; gynecomastia;
D O I：
10.20996/1819-6446-2015-11-2-177-181
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
引用
收藏
页码：177 / 181
页数：5
相关论文
共 50 条
  • [31] Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
    Arai, Kiyoshi
    Homma, Tsuyoshi
    Morikawa, Yuka
    Ubukata, Naoko
    Tsuruoka, Hiyoyuki
    Aoki, Kazumasa
    Ishikawa, Hirokazu
    Mizuno, Makoto
    Sada, Toshio
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 761 : 226 - 234
  • [32] Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure
    Lofman, Ida
    Szummer, Karolina
    Olsson, Henrik
    Carrero, Juan-Jesus
    Lund, Lars H.
    Jernberg, Tomas
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (14):
  • [33] Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
    Pereira, Sofia S.
    Carvalho, Liliana
    Costa, Madalena M.
    Melo, Armindo
    Ferreira, Isabel M. P. L. V. O.
    Gomez-Sanchez, Celso E.
    Monteiro, Mariana P.
    Vinson, Gavin
    Pignatelli, Duarte
    BIOMEDICINES, 2021, 9 (04)
  • [34] Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
    Lee, Seung-Eun
    Kim, Dong-Lim
    Kim, Nan Hee
    ENDOCRINOLOGY AND METABOLISM, 2023, 38 (01) : 43 - 55
  • [35] The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity
    Nielsen, Finn Thomsen
    Jensen, Boye L.
    Hansen, Pernille B. L.
    Marcussen, Niels
    Bie, Peter
    BMC NEPHROLOGY, 2013, 14
  • [36] The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy
    Goenka, Luxitaa
    Padmanaban, Raghavan
    George, Melvin
    CURRENT CLINICAL PHARMACOLOGY, 2019, 14 (02): : 78 - 83
  • [37] Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor
    Rogerson, FM
    Yao, YH
    Smith, BJ
    Fuller, PJ
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (10): : 704 - 709
  • [38] The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure
    Young, Morag J.
    Kanki, Monica
    Karthigan, Nikshay
    Konstandopoulos, Penny
    ENDOCRINOLOGY, 2021, 162 (11)
  • [39] Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys
    Yamada, Makiko
    Takei, Makoto
    Suzuki, Eiko
    Takakusa, Hideo
    Kotsuma, Masakatsu
    Washio, Takuo
    Murayama, Nobuyuki
    Inoue, Shin-ichi
    Izumi, Takashi
    XENOBIOTICA, 2017, 47 (12) : 1090 - 1103
  • [40] A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist
    Zhai, Shuhui
    Ma, Baisheng
    Chen, Weiwei
    Zhao, Qini
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
12345